Muscarinic modulation of human electroencephalography (EEG) activity using scopolamine

INTERVENTION: Arm 1: A single intravenous infusion of 4 µg/kg scopolamine hydrobromide given over 15 minutes under clinical observation Arm 2: A single intravenous infusion of 5 µg/kg scopolamine hydrobromide given over 15 minutes under clinical observation Arm 3: A single intravenous infusion of 6 µg/kg scopolamine hydrobromide given over 15 minutes under clinical observation CONDITION: Major depression; ; Major depression Mental Health ‐ Depression PRIMARY OUTCOME: Power spectral density of the eyes‐open EEG[Collected at 5, 10, 15, 20, 30, 60, 120 and 240 minutes relative to the start of the infusion] SECONDARY OUTCOME: Pharmacokinetic parameters of scopolamine in blood including Cmax, AUC, T1/2, Clearance and Volume of distribution[Blood samples collected at 5, 10, 15, 20, 30, 60, 120 and 240 minutes relative to the start of the infusion] INCLUSION CRITERIA: • Male or female, aged 18 years or above and less than 60. • In the Investigators’ opinion, is able and willing to comply with all trial requirements. • Participant is willing and able to give informed consent for participation in the trial.